^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    CANCER:

    Castration-Resistant Prostate Cancer

    Associations

    News

    Trials
    1d
    Phase 3 Study of Xaluritamig vs Cabazitaxel or Second Androgen Receptor-Directed Therapy in Participants With Progressive Metastatic Castration-Resistant Prostate Cancer (XALute) (clinicaltrials.gov)
    P3, N=675, Recruiting, Amgen | Active, not recruiting --> Recruiting
    Enrollment open
    |
    Xtandi (enzalutamide) • abiraterone acetate • cabazitaxel • xaluritamig (AMG 509)
    2d
    Phase 1 Study of OP-3136 in Advanced or Metastatic Solid Tumors (clinicaltrials.gov)
    P1, N=180, Recruiting, Olema Pharmaceuticals, Inc. | N=48 --> 180
    Enrollment change • First-in-human
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor)
    |
    HER-2 negative
    |
    fulvestrant • palazestrant (OP-1250)
    2d
    A Study of Valemetostat (DS-3201b) in Combination With Darolutamide in Metastatic Castration Resistant Prostate Cancer (mCRPC) (clinicaltrials.gov)
    P1, N=60, Recruiting, Daiichi Sankyo | N=13 --> 60
    Enrollment change • Trial initiation date
    |
    KLK3 (Kallikrein-related peptidase 3)
    |
    Nubeqa (darolutamide) • Ezharmia (valemetostat)
    2d
    Exploring the pharmacological mechanisms of resibufogenin in castration-resistant prostate cancer via network pharmacology and experimental validation. (PubMed, Front Oncol)
    This study suggests that RBG inhibits malignant phenotypes of CRPC cells and may exert its anti-tumor effects in part through interaction with BRAF and modulation of the MAPK signaling pathway. These findings support RBG as a promising candidate for further study in prostate cancer treatment.
    Journal
    |
    BRAF (B-raf proto-oncogene)
    2d
    USP13 promotes enzalutamide resistance by catalyzing depolyubiquitination of PCMT1 in prostate cancer. (PubMed, Cell Death Dis)
    Notably, inhibition of USP13 significantly decreases prostate tumor growth and improves enzalutamide treatments through PCMT1 suppression. Our studies demonstrate that inhibition of USP13 can offer a viable therapeutic option to overcome enzalutamide resistance in prostate cancer patients with USP13/PCMT1-overexpression.
    Journal
    |
    AR (Androgen receptor) • PCM1 (Pericentriolar Material 1) • USP13 (Ubiquitin Specific Peptidase 13)
    |
    Xtandi (enzalutamide)
    2d
    Radiation Medication (Radium-223 Dichloride) Versus Radium-223 Dichloride Plus Radiation Enhancing Medication (M3814) Versus Radium-223 Dichloride Plus M3814 Plus Avelumab (a Type of Immunotherapy) for Advanced Prostate Cancer Not Responsive to Hormonal Therapy (clinicaltrials.gov)
    P1/2, N=90, Recruiting, National Cancer Institute (NCI) | Trial completion date: Apr 2026 --> Apr 2027 | Trial primary completion date: Apr 2026 --> Apr 2027
    Trial completion date • Trial primary completion date
    |
    Bavencio (avelumab) • peposertib (M3814) • Xofigo (radium Ra-223 dichloride)
    2d
    PI3Kbeta Inhibitor AZD8186 and Docetaxel in Treating Patients Advanced Solid Tumors With PTEN or PIK3CB Mutations That Are Metastatic or Cannot Be Removed by Surgery (clinicaltrials.gov)
    P1, N=23, Completed, National Cancer Institute (NCI) | Active, not recruiting --> Completed | Trial completion date: Oct 2026 --> Oct 2025
    Trial completion • Trial completion date
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PTEN (Phosphatase and tensin homolog) • PIK3CB (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit beta)
    |
    ER positive • HR positive • HER-2 negative • ER positive + HER-2 negative • HER-2 negative + ER positive
    |
    docetaxel • AZD8186
    2d
    Prospective Clinical Trial of 225Ac-LNC1011 in the Treatment of Metastatic Castration-Resistant Prostate Cancer (clinicaltrials.gov)
    P1/2, N=16, Active, not recruiting, First Affiliated Hospital of Fujian Medical University | Recruiting --> Active, not recruiting
    Enrollment closed
    3d
    Genetic Predictors of Progression and Skin Rash in Japanese mCSPC Patients Treated With Apalutamide: CUARTET Study. (PubMed, Cancer Sci)
    This study demonstrated that baseline ctDNA predicts prognosis of Japanese patients with mCSPC receiving apalutamide with ADT and identified potential genetic predictors for treatment-related skin rash. Trial Registration: ClinicalTrials.gov identifier: jRCTs071200040.
    Journal
    |
    AR (Androgen receptor)
    |
    apalutamide
    3d
    Multi-modal circulating cell-free DNA profiling to predict response to docetaxel in metastatic castration-resistant prostate cancer. (PubMed, NPJ Precis Oncol)
    A combined ensemble binary classifier generated through XGBoost integrating these feature sets to predict docetaxel response outperformed models derived from any single feature set, achieving a training area-under-the-ROC curve of 0.87. Pre-cabazitaxel specimens, representing a docetaxel-resistant population, were used for external validation, with a concordance of 79.6% for predicting non-response.
    Journal
    |
    TP53 (Tumor protein P53) • PBX1 (PBX Homeobox 1) • MYBL2 (MYB Proto-Oncogene Like 2) • PDX1 (Pancreatic And Duodenal Homeobox 1) • PHOX2B (Paired Like Homeobox 2B) • ZIC2 (Zic Family Member 2)
    |
    TP53 mutation
    |
    docetaxel • cabazitaxel
    3d
    2022-BRL-501: Clinical Study of Safety and Efficacy of Enhanced PSMA CAR- T in Refractory CRPC (clinicaltrials.gov)
    P1, N=18, Active, not recruiting, Shanghai Changzheng Hospital | Trial completion date: Dec 2025 --> Dec 2026 | Trial primary completion date: May 2025 --> May 2026 | Recruiting --> Active, not recruiting
    Enrollment closed • Trial completion date • Trial primary completion date
    |
    FOLH1 (Folate hydrolase 1)
    |
    FOLH1 expression
    |
    cyclophosphamide • fludarabine IV